Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences

Hepatology

Volumn 34, Issue 3, 2001, Pages 583-589

  Liu, Chun Jen ^a   Chen, Pei Jer ^a   Lai, Ming Yang ^a   Kao, Jia Horng ^a   Chen, Ding Shinn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; LAMIVUDINE; TYROSYLMETHIONYLASPARTYLASPARTIC ACID; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FOLLOW UP; GENOME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPETENCE; IMMUNOGENICITY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MOTIF; TREATMENT OUTCOME; VIRAL GENETICS; VIRUS LOAD;

EID: 84984548357     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.27220     Document Type: Article

References (41)

1. From hepatitis to hepatoma: Lessons from type B viral hepatitis
2. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis
3. Clinical relevance of hepatitis B viral mutations
4. Hepatitis B virus immunopathogenesis
5. Changes in the prevalence of HBeAg-negative mutants hepatitis B virus during the course of chronic hepatitis B
6. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication
7. Significance of pre-S region-defective hepatitis B virus that emerged during exacerbation of chronic type B hepatitis
8. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
9. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
10. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
11. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease
12. Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen
13. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus
14. Complete nucleotide sequences of hepatitis B virus genomes associated with epidemic fulminant hepatitis
15. Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B
16. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation
17. A one-year trial of lamivudine for chronic hepatitis B
18. Lamivudine as initial treatment for chronic hepatitis B in the United States
19. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
20. Lamivudine resistance in immunocompetent chronic hepatitis B
21. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B
22. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
23. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
24. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection: Incidence, predisposing factors and etiology
25. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients
26. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli
27. Changes of serum HBV-DNA in relation to serum transaminase level during acute exacerbation in patients with chronic type B hepatitis
28. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: A 4-year experience
29. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
30. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
31. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
32. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection
33. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
34. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo
35. Most dependent evolution and antigenic classification of the hepadna virus family based on nucleotide sequences
36. Genomic heterogeneity of hepatitis B virus in a 54 year-old women who contracted the infection through materno-fetal transmission
37. Long-term mutation rates in the hepatitis B virus genome
38. Reversion from precore-core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy
39. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers
40. Histological grading and staging of chronic hepatitis
41. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region